Stock SLRX SALARIUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
0.501 USD -5.04% Intraday chart for Salarius Pharmaceuticals, Inc. +1.19% -22.92%
03-25 Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data MT
03-25 Top Premarket Gainers MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data
Top Premarket Gainers
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Salarius Pharmaceuticals, Inc. Announces Update on Hematologic Cancer Phase 1/2 Clinical Trial Be Conducted At the University of Texas MD Anderson Cancer Center
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Sector Update: Health Care Stocks Decline Thursday
Sector Update: Health Care Stocks Slightly Lower Thursday Afternoon
Sector Update: Health Care
Salarius Pharmaceuticals Cutting More Than 50% of Workforce While Reviewing Alternatives
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives
Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
Salaries Pharmaceuticals Closes $6 Million Private Placement
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Salarius Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLRX Stock
  4. News Salarius Pharmaceuticals, Inc.
  5. Other languages